Mehra Details the Importance of PD-L1 Expression in HNSCC Treatment SelectionNovember 25th 2022
Ranee Mehra, MD, discusses the link between PD-L1 expression and increased immunotherapy efficacy in head and neck squamous cell carcinoma, and what future treatment options may look like for patients in this space.
Osimertinib Still Holds The Crown in EGFR-Mutated Non-Small Cell Lung CancerNovember 19th 2022
As of November 2022, osimertinib is the preferred choice for the frontline treatment of EGFR-mutated non-small cell lung cancer. However, some experts believe that combination chemotherapy plus EGFR TKI will become a standard frontline treatment.
Distress in Advanced Cancer May Be Alleviated With Psychedelic-Assisted PsychotherapyNovember 15th 2022
Psychiatric distress and existential distress are associated with poor outcomes in patients with advanced cancers and treatment options such as psychotherapy have demonstrated limited effectiveness.
HRD, BRCA Status May Inform PARP Inhibitor Suitability in Advanced Ovarian CancerNovember 12th 2022
During the 40th Annual Chemotherapy Foundation Symposium, Eirwen M. Miller, MD, evaluated the safety and efficacy profiles of different PARP inhibitor therapies for patients with advanced ovarian cancer.